This inventor holds 20 USPTO granted patents and 9 published patent applications and 2 EPO patents. Top assignees: Hyundai Motor Company, Seoul National University, Kia Corporation. Active years: 2013-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Daejeon, KR (2018)
- Seoul, KR (2013 - 2022)
Company Filing History:
7 out of 20,267 
7 out of 1,779 
5 out of 5,750 
Years Active: 2013-2026
Title: Hee Chan Kim: Innovator in Immunological Therapeutics
Introduction
Hee Chan Kim is an inventive researcher based in Daejeon, South Korea, known for his groundbreaking work in the field of immunology. With a focus on developing innovative therapeutic solutions, he has made significant strides in creating targeted antibodies that could revolutionize treatment approaches for various immunological diseases.
Latest Patents
Hee Chan Kim holds a notable patent for an "Anti-TNF-α/CXCL10 double-targeting antibody and use thereof." This pioneering invention pertains to a bispecific antibody designed to simultaneously bind to tumor necrosis factor-alpha (TNF-α) and C-X-C motif chemokine 10 (CXCL10). The antibody features a unique structure that combines scFv derived from specific antibodies, demonstrating enhanced TNF-α inhibitory activity and potential in preventing or treating immunological diseases.
Career Highlights
Kim is currently associated with Metabolic Engineering Laboratories Co., Ltd., where he continues to contribute to the advancement of therapeutic innovations. His research has not only led to a patent but has also laid down the foundation for future studies in antibody-based treatments for a range of diseases.
Collaborations
During his tenure at Metabolic Engineering Laboratories, Hee Chan Kim has collaborated with esteemed colleagues including Heun-Soo Kang and So-Hyun Park. These partnerships have facilitated impactful research endeavors and have further enriched the scientific discussions surrounding immunological therapies.
Conclusion
Hee Chan Kim represents a dynamic force in the field of immunology, with a clear focus on innovative antibody development. His patent for a dual-targeting antibody exemplifies his commitment to addressing complex immunological challenges. As he continues his research, Kim's work promises to offer new insights and treatments for patients suffering from immunological diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile